The dose dependence of mezlocillin pharmacokinetics was examined in relation to renal function after intravenous doses of 1 and 5 g in 16 subjects with various degrees of renal impairment. Dose and time-average model-independent physiological parameters were calculated from plasma concentration and urinary excretion data. Lack of superimposition of plasma concentration profiles occurred between dosage levels with a twofold exaggeration of areas under the curve produced between doses of 1 and 5 g. Decreased plasma clearances at the higher dose were caused partly by nonlinear renal clearance, but more markedly by dose dependence in nonrenal clearances. At each dosage level, these parameters were examined in relation to creatinine clearances. Plasma and renal clearances exhibited a typical linear correlation with creatinine clearance for each dose level. However, nonrenal clearances demonstrated a linear relationship with creatinine clearance at the 1-g dose, but apparent saturation of this pathway produced lower and relatively constant nonrenal clearance values at the 5-g dose. Mezlocillin pharmacokinetics are thus influenced by both dose and renal function over the dosage range of 1 to 5 g. Saturation in renal clearance and probably in biliary clearance explains the unusual disposition characteristics of mezlocillin observed in this and previously reported studies.
The dose dependence of mezlocillin pharmacokinetics was examined in relation to renal function after intravenous doses of 1 and 5 g in 16 subjects with various degrees of renal impairment. Dose and time-average model-independent physiological parameters were calculated from plasma concentration and urinary excretion data. Lack of superimposition of plasma concentration profiles occurred between dosage levels with a twofold exaggeration of areas under the curve produced between doses of 1 and 5 g. Decreased plasma clearances at the higher dose were caused partly by nonlinear renal clearance, but more markedly by dose dependence in nonrenal clearances. At each dosage level, these parameters were examined in relation to creatinine clearances. Plasma and renal clearances exhibited a typical linear correlation with creatinine clearance for each dose level. However, nonrenal clearances demonstrated a linear relationship with creatinine clearance at the 1-g dose, but apparent saturation of this pathway produced lower and relatively constant nonrenal clearance values at the 5-g dose. Mezlocillin pharmacokinetics are thus influenced by both dose and renal function over the dosage range of 1 to 5 g. Saturation in renal clearance and probably in biliary clearance explains the unusual disposition characteristics of mezlocillin observed in this and previously reported studies.
Meziocillin is a semisynthetic ureidopenicillin with pharmacokinetic properties similar to those of other penicillins in that it exhibits a small volume of distribution and undergoes a mixed degree of renal and nonrenal elimination. However, the drug appears unusual in that its disposition is markedly nonlinear. Bergan (4) observed a decrease in renal clearance (C1R) from 19 to 13 liters per h over a 1-to 5-g dosage range of mezlocillin given to normal volunteers. The fall in nonrenal clearance (ClNR) was even greater as values of 12 and 4 liters per h were observed at these dosage extremes. The secondary clearance mechanism involves an appreciable degree of biliary excretion of the drug (6), which is decreased in the presence of probenecid (20) .
The implications of these processes in patients with renal impairment have not been fully explored. Although several studies of mezlocillin disposition in uremic patients have been carried out (5, 9, 12, 13) , none has involved crossover evaluation of low and high dosages of the drug in the pharmacokinetic elaboration of the data in patients with various degrees of renal impairment. This was the purpose of our investigation.
MATERIALS AND METHODS Subjects. Sixteen ambulatory adult volunteers who gave informed consent for the study were initially separated into three groups based on renal function ( were measured with an agar-weli diffusion assay (3).
The medium was 1.5% nutrient agar (Difco Laboratories), and the bioassay organism was a spore suspension ofBacillus subtilis (Difco; ATCC 6633). Mezlocillin standards ranging from 80 to 0.625 ,g/ml were prepared in human serum and urine. Patient samples with concentrations greater than 80 ,g/ml were diluted with serum or urine appropriately. Plates were incubated at 37°C for 12 h, and triplicate zone diameters were measured on an antibiotic zone reader. The within-day coefficients of variation were 3.1 and 2.6% for the low and high assay extremes, whereas the between-day coefficients of variation were 8.0 and 9.5%, respectively.
Pharmacokinetics. The disposition of mezlocillin was described initially in terms of the SHAM (slope, height, area, moment) properties of the curves (10) . This approach is gaining increased use in pharmacokinetics as it permits calculation of the essential parameters of interest without the need to cast the equations in the complex forms which reflect specific compartmental models. This both simplifies and makes more uniform the data-fitting process and allows the equations to be described more compactly for any number of exponential terms (10 
and the first moment (AUTC) was calculated from:
Assuming a common mammillary model with clear- ance from the central compartment, the following dose and time-average pharmacokinetic parameters were calculated from the dose (Do) and SHAM properties (10):
i-1
where Vc is the volume of the central compartment; Clp = DO/AUC (5) where Clp is plasma clearance; V" = Clp'AUTC/AUC (6) where V, is the steady-state volume of distribution.
Similarly, the mean CIR was obtained from the total urinary recovery (An):
The CINR was calculated by difference:
All but one Cp-versus-t curve was biexponential; the values of Vc could not be generated for the monoexponential curve.
Clearance data were normalized for body surface area (1.73 m2), whereas distribution volumes are expressed as distribution coefficients (liters per kilogram) (10).
Statistics. Regression analyses usually involved use of the weighted perpendicular least-squares method for fitting data where both values are subject to error (17) . The paired t-test was employed for the examination of crossover pharmacokinetic parameters (18) .
RESULTS
Disposition pattern. The plasma concentrations and excretion rates of 1-and 5-g (normalized to 1 g by dividing by 5) doses of mezlocillin are shown for a subject with normal renal function ( Fig. 1) and for a subject with impaired renal function (Fig. 2) . Both figures illustrate the typical biexponential pattern and lack of superimposition of the normalized data. The AUC values for the 5-g dose, when normalized (divided by 5) were 2.00 ± 0.44 times greater than that of the 1-g dose at all levels of renal function. These differences were statistically significant (t = 4.97, P < 0.001).
Elimination clearances. The Clp of mezlocillin obtained after 1-and 5-g doses are shown in relation to CICR in Fig. 3 . In this and subsequent graphs, crossover data can be evaluated by vertical assessment of patients at a specific CICR. However, small differences in CICR sometimes were found between studies in individual patients (Table 1) .
To evaluate the dual effects of dose and renal function, the experimental data are usually shown in the form of regression plots. This also obviates the need for arbitrary splitting of patients into subgroups based on CICR clusters.
The Clp values obtained after 1-g doses of mezlocillin were appreciably greater than those after the 5-g dosage (t = 7.97, P < 0.001). a ratio of CIR-1 g/ClR-5 g averaging 1.29 ± 0.35 (t = 3.12, P < 0.01). Both sets of ClR data displayed the typical correlation with CICR. The somewhat greater CIR occurring at higher plasma concentrations accounts for the lack of parallelism in the decline of plasma concentrations and excretion rates ( Fig. 1 and 2 ). This does not 5g9 allow simultaneous curve-fitting of these functions in each subject.
The total urinary recoveries of mezlocillin are shown in Fig. 5 . As anticipated, renal impairment resulted in a greater fraction of the dose being eliminated by nonrenal routes. However, the percent urinary recoveries of drug were generally greater (by 1.68 + 0.56-fold) for the 5-g dose (t = 6.22, P < 0.001). A specific function or regression relationship cannot be applied to these data because they reflect the multiple effects of dose and CICR, ClR, and ClNR processes.
The ClNR values for mezlocillin are shown in Fig. 6 CIR of mezlocillin (Fig. 4) exceeded the CICR only slightly (mean ratio = 1.12). As the antibiotic is moderately (16 to 42%) bound to plasma proteins (Miles Pharmaceuticals, personal communication), an appreciable fraction of the drug in plasma must undergo active tubular secretion. This is supported by data of Verbist et al. (20) , who found that probenecid reduces the CIR of mezlocillin by about one half. Saturation of the tubular secretory mechanism of mezlocillin is the probable explanation for the reduction in ClR with dose. This concentration-dependent mechanism is common to weak acids (22) . The dual nonlinear and ClCR-dependent properties of CINR are of considerable interest. It is unusual to find a secondary clearance mechanism so strongly correlating with renal function.
An appreciable component of the ClNR appears to be biliary excretion, as Brogard et al. (6) report 3 to 30% of a dose of mezlocillin excreted in bile. An additional portion of the dose is probably degraded in serum and other body fluids (23) . The biliary process may involve active transport, as Verbist and co-workers (20) found that probenecid treatment is accompanied by a 31% reduction in CINR in human subjects. Such a transport mechanism may explain the lower ClNR values which we found at the 5-g dose of mezlocillin (Fig. 6) . Similar results can be observed in the data of Kampf et al. (12) AUC c (9) where c is a time-average plasma concentration which, when multiplied by T, produces a given AUC. If a standard dose of 5 g/6 h is accepted as a reasonable starting dose for patients with good renal function (Miles Pharmaceuticals, personal communication), then dosage adjustments based on 5 g given at various intervals can be sought in treating patients with renal impairment. For the 5-g dose, the Clp can be predicted from: CIP = 0.95 + 1.44 CICR (liters h 1 1.73 m-2) (10) as seen in Fig. 3 . Thus the combination of equations 9 and 10 yields the following solution forr: (11) where the units of CICR are liters per hour per 1.73 M2.
Since subjects with normal renal function who receive a 5-g dose of mezlocillin every 6 h would achieve a c of 87 mg/liter (AUC/6), their quotient ANTIMICROB. AGENTS CHEMOTHER.
of DJc 58 liters h-1 1.73 m2, which appears in the numerator above.
Thus equation 11 can be used to generate the intervals for giving 5-g/70 kg doses of the drug shown in Table 2 . These calculations are approximate and conservative and are based both on the parameters from and the hypothesis that 5-g doses of mezlocillin are appropriate. If more frequent doses are given, it should be recognized that accumulation will occur. These preliminary guidelines evolve from pharmacokinetic principles, and larger doses may be warranted in patients with severe infections, smaller doses may be needed if hepatic dysfunction is present, and any final dosage recommendations should be based on clinical experiences with such dosages in the types of patients requiring mezlocillin therapy.
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